MedPath

Comparison of effectiveness and safety of Topical clindamycin vs minocycline vs ozenoxacin in patients of Acne vulgaris

Phase 3
Conditions
Health Condition 1: L700- Acne vulgaris
Registration Number
CTRI/2024/03/064118
Lead Sponsor
OT APPLICABLE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients with Mild papulopustular Acne fairly localized inflamed and non-inflamed lesions, superficial inflammatory lesions being less than 5mm in diameter according to European evidence based S3 acne guidelines

Exclusion Criteria

Patients with mild comedonal acne

Patients with moderate or severe acne

Patients who have been regularly using anti acne medications since the last 30 days

Patients with acne conglobate, acne fulminans or drug-induced acne

Patients with history of hypersensitivity to clindamycin, minocycline or ozenoxacin

Patients who are unwilling or unable to comply with the study proceedings to give written, informed consent

Pregnant or lactating women

Patients with history of photosensitivity

Hormonal or endocrine or autoimmune abnormality

Topical Steroid Dependent Face

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
number of total lesion count, seperating the inflammatory and non-inflammatory lesions, evaluators global acne severity score, investigators global assessment score, patients assessment scoreTimepoint: every monthly for 3 months
Secondary Outcome Measures
NameTimeMethod
presence of scaling, erythema, burning, itching, stingingTimepoint: every monthly for 3 months
© Copyright 2025. All Rights Reserved by MedPath